Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Comparison of 111In-DOTA-NOC and 111In-DOTA-TATE Distribution in the Target and Dose-limiting Tissues: Conflicting Results In Vitro and In Vivo

JAN CIHLO, LUDMILA MELICHAROVÁ, MILOS PETRIK, ALICE LAZNICKOVA and MILAN LAZNICEK
Anticancer Research July 2008, 28 (4B) 2189-2195;
JAN CIHLO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUDMILA MELICHAROVÁ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MILOS PETRIK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALICE LAZNICKOVA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MILAN LAZNICEK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: laznicek@faf.cuni.cz
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: In this study, some important biological characteristics of two radiolabelled somatostatin analogues 111In-DOTA-1-Nal3-octreotide (DOTA-NOC) and 111In-DOTA-Tyr3-octreotate (DOTA-TATE) were compared. Materials and Methods: Rats were used for in vivo biodistribution experiments and in vitro cell models (OK and AR42J cell lines) were used for simulating the internalization in the kidney and in subtype 2 somatostatin receptor (SSTR2)-positive tissues, respectively. Results: Significantly higher radioactivity concentrations in rat organs with high density of somatostatin receptors after 111In-DOTA-NOC administration in comparison with 111In-DOTA-TATE were observed. The predominant urine excretion was associated with accumulation of the radioactivity in the kidney, where higher retention of 111In-DOTA-TATE compared to 111In-DOTA-NOC was detected. In the OK cell line the opposite results were found. No significant differences in the in vitro internalization and externalization of radioactivity to AR42J cell line were found for either peptide suggesting their same affinity for SSTR2. Conclusion: Preclinical experiments indicated that 111In-DOTA-NOC is a very promising peptide for somatostatin receptor-positive tumour visualization. The conflict between the in vitro and in vivo kidney handling showed that the transfer of results from in vitro to in vivo conditions and their interpretation should be performed very carefully because both types of experiments can be affected by different factors, making their simple comparison difficult.

  • Somatostatin analogues
  • 111In-DOTA-1-Nal3-octreotide
  • 111In-DOTA-Tyr3-octreotate
  • tumour targeting
  • renal handling
  • biodistribution
  • AR42J cells
  • OK cells

Footnotes

  • Received February 14, 2008.
  • Revision received April 22, 2008.
  • Accepted May 8, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4B)
Anticancer Research
Vol. 28, Issue 4B
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of 111In-DOTA-NOC and 111In-DOTA-TATE Distribution in the Target and Dose-limiting Tissues: Conflicting Results In Vitro and In Vivo
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Comparison of 111In-DOTA-NOC and 111In-DOTA-TATE Distribution in the Target and Dose-limiting Tissues: Conflicting Results In Vitro and In Vivo
JAN CIHLO, LUDMILA MELICHAROVÁ, MILOS PETRIK, ALICE LAZNICKOVA, MILAN LAZNICEK
Anticancer Research Jul 2008, 28 (4B) 2189-2195;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Comparison of 111In-DOTA-NOC and 111In-DOTA-TATE Distribution in the Target and Dose-limiting Tissues: Conflicting Results In Vitro and In Vivo
JAN CIHLO, LUDMILA MELICHAROVÁ, MILOS PETRIK, ALICE LAZNICKOVA, MILAN LAZNICEK
Anticancer Research Jul 2008, 28 (4B) 2189-2195;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Receptor Affinity and Preclinical Biodistribution of Radiolabeled Somatostatin Analogs
  • Google Scholar

More in this TOC Section

  • C-myc Oncogene Numerical Imbalances Analysis in Laryngeal Squamous Cell Carcinoma
  • Association of Interleukin-12A Genotypes With Nasopharyngeal Carcinoma Risk
  • Immunogenicity of Neoantigens in Colorectal Cancer: Potential Influence of Tumor Mutation Burden, Stages, and Metastasis
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire